The Meridian Reformer combines luxury design, immersive instruction and the Echelon Fit ecosystem into a next-generation connected Pilates experience.CHATTANOOGA, Tenn., June 9, 2026 /PRNewswire/...
Agreement expected to supply 40,000 tons per year of plastic waste feedstock, representing approximately 50% of the expected requirement for Abundia’s first Cedar Port plant
WASHINGTON, June 9, 2026 /PRNewswire/ -- Vice President Mike Pence will discuss his new book, "What Conservatives Believe," and detail his vision for the...
ANCHORAGE, Alaska, June 9, 2026 /CNW/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide an update on the...
GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, Teva Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Lupin Limited, STADA Arzneimittel AG, Hikma Pharmaceuticals plc, Torrent Pharmaceuticals Ltd., Endo International plc, Aurobindo Pharma Limited, Sawai Pharmaceutical Co. Ltd., Mallinckrodt plc, Amneal Pharmaceuticals Inc and others.
SEOUL, South Korea, June 9, 2026 /PRNewswire/ -- Beauty of Joseon has been recognized by global market intelligence company Euromonitor International as the "Global No.1...
High-accuracy energy measurements and photon-level data acquisition on a single chipATSUGI, Japan, June 9, 2026 /PRNewswire/ -- Sony Semiconductor Solutions Corporation (Sony) today announced...
High-accuracy energy measurements and photon-level data acquisition on a single chipATSUGI, Japan, June 8, 2026 /PRNewswire/ -- Sony Semiconductor Solutions Corporation (Sony) today announced...